Review of Sativex for multiple sclerosis spasticity
Clinical trials showed Sativex spray reduced MS spasticity severity and improved daily functioning, with side effects mostly mild to moderate and manageable through gradual dose increases.
Quick Facts
What This Study Found
This review compiled clinical trial evidence for Sativex oromucosal spray in MS-related spasticity. Randomized controlled trials reported reductions in spasticity severity when Sativex was added to existing treatments, along with improved ability to perform daily activities.
Both patients and caregivers perceived functional improvement. Common adverse events included dizziness, diarrhea, fatigue, nausea, headache, and somnolence, but these were generally mild to moderate and could be substantially reduced by gradually increasing the dose rather than starting at full dose.
The review positioned Sativex as a useful add-on therapy when existing spasticity medications provided insufficient relief.
Key Numbers
Common adverse events: dizziness, diarrhea, fatigue, nausea, headache, somnolence. Side effects were mild-to-moderate intensity. Gradual uptitration markedly reduced adverse event incidence.
How They Did This
Review of published randomized controlled trials and clinical experience data for Sativex in MS spasticity. Included the GW Pharmaceuticals integrated safety analysis.
Why This Research Matters
MS spasticity significantly impacts quality of life, and existing drug treatments often provide limited benefit with poor tolerability. Sativex offered an additional option, particularly for patients who had not responded adequately to conventional anti-spasticity medications.
The Bigger Picture
Sativex became one of the first cannabis-derived prescription medicines approved in multiple countries for MS spasticity. Its clinical profile helped shift the conversation about medical cannabis from anecdotal use to evidence-based prescribing.
What This Study Doesn't Tell Us
Review focused on initial clinical trial data. Long-term safety and efficacy data was still accumulating. The subjective nature of spasticity measurement makes blinding challenging. Industry data was included.
Questions This Raises
- ?Does Sativex maintain efficacy over years of use?
- ?Which MS patients benefit most?
- ?Can responders be identified early to avoid unnecessary treatment?
Trust & Context
- Key Stat:
- Gradual dose uptitration markedly reduced side effects
- Evidence Grade:
- Review of randomized controlled trials. Good quality evidence base, though the review itself was narrative rather than systematic.
- Study Age:
- Published in 2011. Sativex has since been approved for MS spasticity in multiple countries with additional long-term safety data.
- Original Title:
- THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
- Published In:
- Expert review of neurotherapeutics, 11(5), 627-37 (2011)
- Authors:
- Sastre-Garriga, Jaume, Vila, Carlos(4), Clissold, Stephen, Montalban, Xavier
- Database ID:
- RTHC-00519
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does Sativex cure MS spasticity?
No. Sativex was studied as an add-on to existing treatments and reduced symptom severity rather than curing the underlying condition. It was most beneficial for patients whose spasticity was not adequately controlled by conventional medications.
How are side effects managed?
The key strategy is gradual dose increase (uptitration) rather than starting at full dose. This approach markedly reduced the incidence of dizziness, fatigue, and nausea that occurred when starting at higher doses.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00519APA
Sastre-Garriga, Jaume; Vila, Carlos; Clissold, Stephen; Montalban, Xavier. (2011). THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.. Expert review of neurotherapeutics, 11(5), 627-37. https://doi.org/10.1586/ern.11.47
MLA
Sastre-Garriga, Jaume, et al. "THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.." Expert review of neurotherapeutics, 2011. https://doi.org/10.1586/ern.11.47
RethinkTHC
RethinkTHC Research Database. "THC and CBD oromucosal spray (Sativex®) in the management of..." RTHC-00519. Retrieved from https://rethinkthc.com/research/sastre-garriga-2011-thc-and-cbd-oromucosal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.